Vimian Group Ab · OMXSTO:VIMIAN
Vimian Group Ab — Q2 2026 Earnings Presentation
18 slides from Vimian Group Ab's earnings presentation, Jul 17, 2026
Slide 1: Q2 presentation
Improving animal health through science and technology for better lives Q2 presentation July 2026
Slide 2: Q2 Highlights
Q2 Highlights Business momentum well ahead of the market / Strong revenue and earnings growth with margin expansion / Double-digit organic growth ahead of the market / Active M&A pipeline across all segments / ESG rating upgraded to highest score ‘AAA’ with MSCI Page 3
Slide 3: A strong quarter across all segments
A strong quarter across all segments Revenue and Adj. EBITA x% Adj EBITA margin x% Organic growth (%) Q2 development / Net revenue +17% 130 121.6 / 17% revenue growth to EUR 121.6m 120 116.0 107.5 29.7 109.0 29.2 110 104.9 28.3 104.3 104.3 30 100 25.4 25.5 26.1 / 12% organic growth with double-digit
Slide 4: Specialty Pharma
Specialty Pharma Continued strong business momentum +14% Organic revenue growth / 14 per cent organic growth with strong contribution from Specialty Pharmaceuticals and +13% Specialised Nutrition Adj. EBITA growth / Growth in US Specialised Nutrition supported by national sales campaign / Continued
Slide 5: Specialty Pharma: Innovation at the core of our growth strategy
Specialty Pharma: Innovation at the core of our growth strategy Organic Inorganic 1 2 3 4 Expand footprint Innovation Education M&A Number of new products launched per quarter 75 20 21 20 23 21 25 Products launched L12M 18 17 13 13 12 10 >60 Products in pipeline Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q
Slide 6: Specialty Pharma: Accelerating our pharmaceuticals and diagnostics innovation agenda
Specialty Pharma: Accelerating our pharmaceuticals and diagnostics innovation agenda Allergy PAX2 – enhancing the world’s leading allergy test Cement position as global #1 in veterinary / Added 25 novel allergens identified by Nextmune allergology through unique data driven innovation / Commercial l
Slide 7: Specialty Pharma: Continuing to launch OTC products within niches with unmet medical needs
Specialty Pharma: Continuing to launch OTC products within niches with unmet medical needs Dermatology IryLac – expanding into ophthalmology Expand into adjacent therapeutic areas through / First in-eye ophthalmology OTC product offered by Nextmune science backed solutions / Preservative-free eye dr
Slide 8: MedTech
MedTech Return to double-digit growth +11% Organic revenue growth / 11 per cent organic growth with double-digit growth in both dental and orthopedics / US orthopedics returned to growth on the back of operational improvements +27% Adj. EBITA growth / Margin uplift driven by bolt-on acquisitions in
Slide 9: Veterinary Services
Veterinary Services Continued strong growth and expansion ahead +10% Organic revenue growth / 10 per cent organic growth with momentum in member growth and strategic partnerships / 11,900 members at the end of Q2 +18% Adj. EBITA growth / Margin reflects mix effects from acquisitions and communicated
Slide 10: Diagnostics
Diagnostics Focus on companion animal +7% Organic revenue growth / 7 per cent organic growth / Strong growth in I-Vet - continuing to strengthen companion animal offering +32% Adj. EBITA growth / Margin slightly impacted by product mix with higher levels of extraction sales Revenue and Adj. EBITA Ad
Slide 11: M&A developments
M&A developments Four acquisitions year-to-date Acquisition Segment Closing Revenues I-Vet Diagnostics March 2026 EUR 5.6m Favna Vet Services March 2026 EUR 4.3m Vetsave Vet Services May 2026 EUR 1.6m Verona Pet Diagnostics July 2026 EUR 0.4m Page 12
Slide 12: Creating a sustainable leader in animal health
Creating a sustainable leader in animal health Sustainability strategy Animals People Planet We improve animal health We create a great place to work in We minimize our environmental through innovation, education, an engaging and inclusive footprint by reducing emissions. and responsible treatments.
Slide 13: Second Quarter Financials
2 Second Quarter Financials Page 14
Slide 14: Q2 Income Statement
EURm Q2 2026 April – June Q2 2025 April – June Q2 Income Statement Net revenue 121.6 104.3 / Operating profit (EBIT) grew 54% to EUR 22.3m Adjusted EBITA 29.7 25.4 / Items affecting comparability of EUR -0.9m (-5.3) Adjusted EBITA margin (%) 24.5% 24.3% / Net financial items of EUR -8.0m (-1.6) Item
Slide 15: Q2 Cash Flow
EURm Q2 2026 April – June Q2 2025 April – June Q2 Cash Flow EBIT 22.3 14.5 / NWC EUR 114.1m at 26 per cent of revenue per end of June Cash flow from operating activities • Compared to end of March 2026, net working capital increased by EUR 19.2 30.0 before change in NWC 21.3m Change in NWC - 15.4 -
Slide 16: Net Debt and Leverage
Leverage Net Debt (EUR m) Net Debt and Leverage 280 274 / Net debt per 30 June 2026 EUR 273.7m 261 258 260 254 245 / Cash and cash equivalents EUR 51.6m 240 222 220 212 / Net Debt / LTM Proforma Adjusted EBITDA 2.1x 200 180 160 140 140 120 2.0x 2.1x 2.1x 2.0x 2.1x 2.1x 100 1.8x 80 1.3x 60 40 20 0 3Q
Slide 17: Concluding remarks
Concluding remarks / Successful first half year / Strong organic growth ahead of the market / Four acquisitions closed year-to-date – highly active M&A pipeline / Well-positioned with robust strategy in attractive market Page 18
Slide 18: T™
T™